Sumanta K. Pal, MD, associate professor of the Department of Medical Oncology and Experimental Therapeutics at City of Hope, discusses the data he considers when treating patients with metastatic urothelial carcinoma.
Sumanta K. Pal, MD, associate professor of the Department of Medical Oncology and Experimental Therapeutics at City of Hope, discusses the data he considers when treating patients with metastatic urothelial carcinoma.
While many agents have been approved for this disease, Pal says the decision will rely heavily on the physician’s comfort level with each of the agents when deciding which to use.
In Pal’s opinion, there is the highest amount of evidence with atezolizumab (Tecentriq) and pembrolizumab (Keytruda). When looking at data for atezolizumab from the IMvigor211 trial, many physicians found the results to be negative. However, one particular subset of patients in this study was given atezolizumab in comparison to agents like taxanes.
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More